Evaluation of Positive Inotropic Activity Induced bya Danazol Derivative in Isolated Rat Heart Model

DOI: 10.4236/pp.2013.44058   PDF   HTML     3,960 Downloads   5,647 Views  


There is scarce information about the effects of danazol and its derivatives at cardiovascular level. In addition, to date the cellular site and mechanism of action of danazol at the cardiovascular level is very confusing. In order to clarify those phenomena in this study, a danazol derivative was synthesized with the objective of evaluating its activity on perfusion pressure and coronary resistance and comparing this phenomenon with the effect exerted by danazol. The Langendorff technique was used to measure changes on perfusion pressure and coronary resistance in an isolated rat heart model in the absence or presence of danazol and its derivative. Additionally, to characterize the molecular mechanism involved in the inotropic activity induced by danazol derivative was evaluated by measuring left ventricular pressure in the absence or presence of following compounds; flutamide, prazosin, metoprolol, indomethacin and nifedipine. The results showed that danazol derivative significantly increased the perfusion pressure and coronary resistance in comparison with the control conditions and danazol. Additionally, other data indicate that the danazol derivative increases left ventricular pressure in a dose-dependent manner; nevertheless, this phenomenon was significantly inhibited by flutamide. These data suggest that danazol derivative induces positive inotropic activity through of the activation androgen receptor.

Share and Cite:

L. Figueroa-Valverde, F. Díaz-Cedillo, E. García-Cervera, E. Gómez, M. López-Ramos, M. Rosas-Nexticapa, R. Mendoza-López, I. May-Gil and A. Sarao, "Evaluation of Positive Inotropic Activity Induced bya Danazol Derivative in Isolated Rat Heart Model," Pharmacology & Pharmacy, Vol. 4 No. 4, 2013, pp. 406-415. doi: 10.4236/pp.2013.44058.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] A. Feldman, “Classification of Positive Inotropic Agents,” Journal of the American College Cardiology, Vol. 22, No. 4, 1993, pp. 1223-1227. doi:10.1016/0735-1097(93)90441-3
[2] E. Braunwald and M. Bristow, “Congestive Heart Failure: Fifty Years of Progress,” Circulation, Vol. 102, Suppl. 4, 2000, pp. 4-23. doi:10.1161/01.CIR.102.suppl_4.IV-14
[3] J. Kersten, M. Montgomery and S. Pagel, et al., “Levosimendan, a New Positive Inotropic Drug, Decreases Myocardial Infarct Size via Activation of KATP Channels,” Anesthesia & Analgesia, Vol. 90, No. 1, 2000, pp. 5-11. doi:10.1097/00000539-200001000-00003
[4] D. Silverberg, D. Wexler and M. Blum, et al., “The Use of Subcutaneous Erythropoietin and Intravenous Iron for the Treatment of the Anemia of Severe, Resistant Congestive Heart Failure Improves Cardiac and Renal Function and Functional Cardiac Class, and Markedly Reduces Hospitalizations,” Journal of the American College Cardiology, Vol. 35, No. 7, 2000, pp. 1737-1744. doi:10.1016/S0735-1097(00)00613-6
[5] W. Wier and P. Hess, “Excitation-Contraction Coupling in Cardiac Purkinje Fibers. Effects of Cardiotonic Steroids on the Intracellular [Ca2+] Transient, Membrane Potential, and Contraction,” Journal General of Phsiology, Vol. 83, No. 3, 1984, pp. 395-415. doi:10.1085/jgp.83.3.395
[6] A. Clark, “The Mode of Action of Strophanthidin upon Cardiac Tissue,” The Journal of Pharmacology & Experimental Therapeutics, Vol. 5, No. 3, 1914, pp. 215-234.
[7] C. Pignier, M. Keller and B. Vié, et al., “A novel SteroidLike Compound F90927 Exerting Positive-Inotropic Effects in Cardiac Muscle,” Britih Jounal of Pharmacology, Vol. 147, No. 7, 2006, pp. 772-782. doi:10.1038/sj.bjp.0706673
[8] L. Figueroa-Valverde, F. Díaz-Cedillo and M. López-Ramos, et al., “Synthesis of a New Inotropic Steroid Derivative and Its Relationship with log P, π, Rm, Vm, Pc, St,” Asian Journal of Chemistry, No. 23, 2011, pp. 15991604.
[9] M. Gobbini, P. Barassi and A. Cerri, et al., “17 AlphaO-(Aminoalkyl) Oxime Derivatives of 3 Beta, 14 BetaDihydroxy-5 Beta-Androstane and 3 Beta-Hydroxy-14Oxoseco-D-5 Beta-Androstane as Inhibitors of Na(+), K(+)-ATPase at the Digitalis Receptor,” Journal of Medicinal Chemistry, Vol. 44, No. 23, 2001, pp. 3821-3830. doi:10.1021/jm0109208
[10] S. De Munari, A. Cerri and M. Gobbini, et al., “StructureBased Design and Synthesis of Novel Potent Na+, K+ATPase Inhibitors Derived from a 5α, 14α-Androstane Scaffold as Positive Inotropic Compounds,” Journal of Medicinal Chemistry, Vol. 46, No. 17, 2003, pp. 36443654. doi:10.1021/jm030830y
[11] J. Templeton, V. Kumar and D. Cote, et al., “ProgesterOne Derivatives That Bind to the Digitalis Receptor: Synthesis of 14. Beta-Hydroxyprogesterone: A Novel Steroid with Positive Inotropic Activity,” Journal of Medicinal Chemistry, Vol. 30, No. 8, 1987, pp. 1502-1505. doi:10.1021/jm00391a038
[12] J. Maixten, I. Bertrand and G. Leliever, et al., “Efficacy and Safety of the Novel Na+, K+-ATPase Inhibitor 20R 14β-Amino 3β-Rhamnosyl 5β-Pregnan 20β-ol in a Dog Model of Heart Failure,” Arzneimittel-Forschung, Vol. 42, No. 11, 1992, pp. 301-305.
[13] J. Simard, I. Luthy and J. Guay, et al., “Characteristics of Interaction of the Antiandrogen flutamide with the Androgen Receptor in Various Target Tissues,” Molecular and Cellular Endocrinology, Vol. 44, No. 3,1986, pp. 261-270. doi:10.1016/0303-7207(86)90132-2
[14] R. Graham, H. Oates and L. Stoker, et al., “Alpha Blocking Action of the Antihypertensive Agent, Prazosin,” Journal of Pharmacology and Experimental Therapeutic, Vol. 201, No. 3, 1977, pp. 747-752.
[15] C. Bengtsson, G. Johnsson and C. Regardh, “Plasma Levels and Effects of Metoprolol on Blood Pressure and Heart Rate in Hypertensive Patients after an Acute Dose and between Two Doses during Long-Term Treatment,” Clinical Pharmacology Therapeutic, Vol. 17, No. 4, 1975, pp. 400-408.
[16] P. Henry, “Comparative Pharmacology of Calcium Antagonists: Nifedipine, Verapamil and Diltiazem,” The American Journal of Cardiology, Vol. 46, No. 6, 1980, pp. 1047-1058. doi:10.1016/0002-9149(80)90366-5
[17] T. Owen, I. Ehrhart, W. Weidner, et al., “Effects of inDomethacin on Local Blood Flow Regulation in Canine Heart and Kidney,” Experimental Biology and Medicine, Vol. 149, No. 4, 1975, pp. 871-876.
[18] L. Figueroa-Valverde, F. Cedillo, García-Cervera, et al., “Design and Synthesis of N-[2-(2,3-Dimethoxy-strychnidin-10-ylidenamino)-ethyl]-Succinamic Acid 4-Allyl-2methoxy-phenyl Ester,” Bulgarian Chemical Communications, Vol. 45, 2013, in Press.
[19] K. Bayne, “Revised Guide for the Care and Use of Laboratory Animals Available,” The Physiologist, Vol. 9, No. 4, 1996, pp. 208-211.
[20] L. Figueroa-Valverde, F. Díaz-Cedillo, López-Ramos, et al., “Inotropic Activity Induced by Carbamazepine-AlKyne Derivative in an Isolated Heart Model and Perfused to Constant Flow,” Biomedica, Vol. 31, No. 2, 2011, pp. 232-241.
[21] D. Cermik and B. Taylor, “Regulation of HOXA-10 Expression by Testosterone in Vitro and in the Endometrium of Patients with Polycystic Ovary Syndrome,” Journal of Clinical Endocrinology & Metabolism, Vol. 8, No. 1, 2003, pp. 238-243. doi:10.1210/jc.2002-021072
[22] E. Ahlbom, G. Prins and S. Ceccatelli, “Testosterone Protects Cerebellar Granule Cells from Oxidative StressInduced Cell Death through a Receptor Mediated Mechanism,” Brain Research, Vol. 892, No. 2, 2001, pp. 255262. doi:10.1016/S0006-8993(00)03155-3
[23] G. Ashcroft and S. Mills, “Androgen Receptor-Mediated Inhibition of Cutaneous Wound Healing,” Journal of Clinical Investigation, Vol. 110, No. 5, 2002, pp. 615-624. doi:10.1172/JCI15704
[24] L. Figueroa, H. Luna, et al., “Synthesis and Evaluation of the Cardiovascular Effects of Two, Membrane Impermeant, Macromolecular Complexes of Dextran-Testosterone,” Steroids, Vol. 67, No. 7, 2002, pp. 611-619. doi:10.1016/S0039-128X(02)00011-9
[25] M. Yang and J. Fortune, “Testosterone Stimulates the Primary to Secondary Follicle Transition in Bovine Follicles in Vitro,” Biology of Reproduction, Vol. 75, No. 6, 2006, pp. 924-932. doi:10.1095/biolreprod.106.051813
[26] C. Hocht, J. Opezzo, S. Gorzalczany, et al., “Una Aproximación Cinética y Dinámica de Metildopa en Ratas con Coartación Aórtica Mediante Microdiálisis,” Revista Argentina de Cardiologia, Vol. 67, No. 6, 1999, pp. 769773.
[27] S. Tu, F. Fang, C. Miao, et al., “One-Pot Synthesis of 3,4-Dihydropyrimidin-2(1H)-Ones Using Boric Acid as Catalyst,” Tetrahedron Letters, Vol. 44, No. 4, 2003, pp. 6153-6156. doi:10.1016/S0040-4039(03)01466-7
[28] P. Salehi and N. Fard, “Silica Sulfuric Acid: An Efficient and Reusable Catalyst for the One-Pot Synthesis of 3,4Dihydropyrimidin-2(1H)-Ones,” Tetrahedron Letters, Vol. 44, No. 14, 2003, pp. 2889-2891. doi:10.1016/S0040-4039(03)00436-2
[29] R. Yarapathi, S. Kurva and S. Tammishetti, “Synthesis of 3,4-Dihydropyrimidin-2(1H)-Ones Using Reusable Poly(4-vinylpyridine-codivinylbenzene)-Cu(II)complex,” Catalysis Communications, Vol. 5, No. 9, 2004, pp. 511-513. doi:10.1016/j.catcom.2004.06.007
[30] F. Shirini, K. Marjani and H. Nahzomi, “Silica Triflate as an Efficient Catalyst for the Solvent-Free Synthesis of 3,4-Dihydropyrimidin-2(1H)-Ones,” Arkivoc, Vol. 2007, No. 1, 2007, pp. 51-57. doi:10.3998/ark.5550190.0008.106
[31] R. Crossland and K. Servis, “Facile Synthesisof Methanesulfonate Esters,” Journal Organic Chemistry, Vol. 35, No. 9, 1970, pp. 3195-3196. doi:10.1021/jo00834a087
[32] M. Wadie and B. Fam, “Effect of Coronary Vasodilator Drugs on Retrograde Flow in Areas of Chronic Myocardial Ischemia,” Circulation Research, Vol. 15, 1964, pp. 355-365. doi:10.1161/01.RES.15.4.355
[33] L. Figueroa-Valverde, F. Díaz-Cedillo, E. Diaz, et al., “Effect Induced by Hemisuccinate of Pregnenolone on Perfusion Pressure and Vascular Resistance in Isolated Rat Heart,” African Journal of Pharmacy & Pharmacology, Vol. 3, No. 5, 2009, pp. 234-241.
[34] I. Charalampopoulos, E. Dermitzaki, L. Vardouli, et al., “Dehydroepiandrosterone Sulfate and Allopregnanolone Directly Stimulate Catecholamine Production via Induction of Tyrosine Hydroxylase and Secretion by Affecting Actin Polymerization,” Endocrinology, Vol. 146, No. 8, 2005, pp. 3309-3318. doi:10.1210/en.2005-0263
[35] L. Figueroa-Valverde, F. Díaz-Cedillo, M. López-Ramos, et al., “Changes Induced by Estradiol-Ethyl-Enediamine Derivative on Perfusion Pressure and Coronary Resistance in Isolated Rat Heart: L-Type Calcium Channel,” Biomedical Papers, Vol. 155, No. 1, 2011, pp. 27-32. doi:10.5507/bp.2011.018
[36] C. Sheillan, C. Ody, F. Russo, et al., “Differential Aspects of Sex Steroids on Prostaglandin Secretion by Male and Female Cultured Piglet Endothelial Cells,” Prostaglandins, Vol. 26, No. 1, 1983, pp. 3-12. doi:10.1016/0090-6980(83)90069-2
[37] L. Krey, R. Robbins and B. McEwen, “Danazol Suppression of Luteinizing Hormone Secretion: A Role for Danazol-Androgen Receptor Interaction within the BrainPituitary Complex,” Fertility and Sterility, Vol. 35, No. 4, 1981, pp. 467-472.
[38] L. Figueroa-Valverde, E. Diaz-Ku and F. Diaz-Cedillo, “Effects of Danazol and Danazol Hemisuccinate on Perfusión Pressure and Vascular Resistance,” Acta Bioquímica Clínica Latinoamericana, Vol. 44, No. 1, 2010, pp. 37-45.
[39] J. Reckelhoff, H. Zhang, K. Srivastava, et al., “Gender Differences in Hypertension in Spontaneously Hypertensive Rats: Role of Androgens and Androgen Receptor,” Hypertension, Vol. 34, 1999, pp. 920-923. doi:10.1161/01.HYP.34.4.920
[40] A. Caple, D. Seachrist and D. Dunphy, “Sodium-Induced Rise in Blood Pressure Issuppressed by Androgen Receptor Blockade,” American Journal of Physiology, Heart and Circulatory Physiology, Vol. 280, No. 4, 2001, pp. H1793-H1801.
[41] F. Zheng, P. Wang and J. Kuebler, “Flutamide Induces Relaxation in Large and Small Blood Vessels,” Archives of Surgery, Vol. 137, No. 10, 2002, pp. 1180-1186. doi:10.1001/archsurg.137.10.1180
[42] T. Akera and M. Brody, “The Role of Na+, K+-ATPase in the Inotropic Action of Digitalis,” Pharmacology Review, Vol. 29, No. 3, 1977, pp. 187-220.
[43] J. Simard, I. Luthy and J. Guay, “Characteristics of Interaction of the Antiandrogen Flutamide with the Androgen Receptor in Various Target Tissues,” Molecular Andular& Endocrinology, Vol. 44, No. 3, 1986, pp. 261-270.
[44] L. Pierard, C. Berthe, A. Albert, et al., “Haemodynamic Alterations during Ischaemia Induced by Dobutamine Stress Testing,” European Heart Journal, Vol. 10, No. 9, 1989, pp. 783-790.

comments powered by Disqus

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.